143 related articles for article (PubMed ID: 19335218)
1. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.
Diamond P; Labrinidis A; Martin SK; Farrugia AN; Gronthos S; To LB; Fujii N; O'Loughlin PD; Evdokiou A; Zannettino AC
J Bone Miner Res; 2009 Jul; 24(7):1150-61. PubMed ID: 19335218
[TBL] [Abstract][Full Text] [Related]
2. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
Bao L; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
4. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
5. Macrophage Migration Inhibitory Factor (MIF) Supports Homing of Osteoclast Precursors to Peripheral Osteolytic Lesions.
Movila A; Ishii T; Albassam A; Wisitrasameewong W; Howait M; Yamaguchi T; Ruiz-Torruella M; Bahammam L; Nishimura K; Van Dyke T; Kawai T
J Bone Miner Res; 2016 Sep; 31(9):1688-700. PubMed ID: 27082509
[TBL] [Abstract][Full Text] [Related]
6. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
7. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
Pandey MK; Kale VP; Song C; Sung SS; Sharma AK; Talamo G; Dovat S; Amin SG
Exp Hematol; 2014 Oct; 42(10):883-96. PubMed ID: 25034231
[TBL] [Abstract][Full Text] [Related]
8. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
9. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
11. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.
Beider K; Bitner H; Leiba M; Gutwein O; Koren-Michowitz M; Ostrovsky O; Abraham M; Wald H; Galun E; Peled A; Nagler A
Oncotarget; 2014 Nov; 5(22):11283-96. PubMed ID: 25526031
[TBL] [Abstract][Full Text] [Related]
13. Adipocytes enhance expression of osteoclast adhesion-related molecules through the CXCL12/CXCR4 signalling pathway.
Luo T; Liu H; Feng W; Liu D; Du J; Sun J; Wang W; Han X; Guo J; Amizuka N; Li X; Li M
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 27868262
[TBL] [Abstract][Full Text] [Related]
14. The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?
Katz BZ; Tavor S
Leuk Lymphoma; 2009 Jul; 50(7):1067-8. PubMed ID: 19557626
[No Abstract] [Full Text] [Related]
15. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
16. Targeting SDF-1 in multiple myeloma tumor microenvironment.
Bouyssou JM; Ghobrial IM; Roccaro AM
Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
[TBL] [Abstract][Full Text] [Related]
17. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
18. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.
Ersek A; Xu K; Antonopoulos A; Butters TD; Santo AE; Vattakuzhi Y; Williams LM; Goudevenou K; Danks L; Freidin A; Spanoudakis E; Parry S; Papaioannou M; Hatjiharissi E; Chaidos A; Alonzi DS; Twigg G; Hu M; Dwek RA; Haslam SM; Roberts I; Dell A; Rahemtulla A; Horwood NJ; Karadimitris A
J Clin Invest; 2015 Jun; 125(6):2279-92. PubMed ID: 25915583
[TBL] [Abstract][Full Text] [Related]
19. Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis.
Zhu X; Gao J; Ng PY; Qin A; Steer JH; Pavlos NJ; Zheng MH; Dong Y; Cheng TS
J Bone Miner Res; 2016 Mar; 31(3):560-72. PubMed ID: 26363136
[TBL] [Abstract][Full Text] [Related]
20. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma.
Ooi LL; Dunstan CR
J Bone Miner Res; 2009 Jul; 24(7):1147-9. PubMed ID: 19419311
[No Abstract] [Full Text] [Related]
[Next] [New Search]